Biologics Contract Development and Manufacturing Organization (CDMO) Market Forecasts to 2030 - Global Analysis By Product (Biosimilars, Biologics and Other Products), Service (Contract Manufacturing Organization (CMO) and Contract Research Organization (

Biologics Contract Development and Manufacturing Organization (CDMO) Market Forecasts to 2030 - Global Analysis By Product (Biosimilars, Biologics and Other Products), Service (Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO)), Type, End User and By Geography

According to Stratistics MRC, the Global Biologics Contract Development and Manufacturing Organization (CDMO) Market is accounted for $14.54 billion in 2024 and is expected to reach $33.45 billion by 2030 growing at a CAGR of 14.9% during the forecast period. Biological products, such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins, are developed and manufactured with the assistance of specialized service providers known as biologics contract development and manufacturing organizations, or CDMOs. Because they offer experience in fields like cell line development, process optimization, analytical testing, and large-scale production, these organizations are vital to the biopharmaceutical sector. Moreover, biopharma companies can cut costs, expedite product development, and more skillfully navigate complex regulatory environments by collaborating with CDMOs.

According to the International Society for Pharmaceutical Engineering (ISPE), Biologics Contract Development and Manufacturing Organizations (CDMOs) are vital to the pharmaceutical industry, providing essential services that enable the development, scale-up, and commercialization of complex biological products.

Market Dynamics:

Driver:

Growing interest in biologics

The need for more efficient and focused treatments is being driven by the rising global burden of chronic diseases like diabetes, cancer, and autoimmune disorders. Biologics are a preferred option for treatment because of their high specificity and efficacy. The increasing demand for biologics has led pharmaceutical companies to turn to CDMOs for their expertise in meeting production needs in an efficient manner. Additionally, this demand is further fueled by the aging population and biotechnology developments, which are driving the CDMO market's steady growth.

Restraint:

Excessive costs of operations

The high operating costs of producing biologics are one of the main obstacles facing the biologics Contract Development and Manufacturing Organization (CDMO) market. Complex and costly procedures, such as advanced cell culture techniques, purification techniques, and strict quality control measures, are involved in the manufacturing of biologics. Costs are further increased by the requirement for specialized facilities, highly qualified workers, and cutting-edge technologies. Furthermore, to comply with regulations and industry standards, CDMOs have to make large capital expenditures on equipment and infrastructure, which can be very expensive.

Opportunity:

Utilizing cutting-edge manufacturing technologies

Modern manufacturing techniques like automation, continuous bioprocessing, and single-use systems offer CDMOs great chances to improve both the quality of their output and operational efficiency. By lowering production costs and increasing scalability, these technologies can also lower the risk of contamination. Moreover, CDMOs can reinforce their competitive advantage and satisfy the increasing market for superior biologics by putting these innovations to use.

Threat:

Insufficiently skilled workforce

A highly skilled and specialized workforce is needed in the biologics industry, including experts in cell biology, bioprocess engineering, and regulatory affairs. Nonetheless, there is a dearth of professionals with the knowledge and experience needed to assist in the creation and production of biologics throughout the world. The inability of CDMOs to attract and retain skilled staff may impede their ability to expand and operate more efficiently. Additionally, in order to attract and retain top talent, CDMOs must provide competitive salaries, training programs, and opportunities for career development. This is because there is fierce competition for skilled workers.

Covid-19 Impact:

The market for biologics contract development and manufacturing organizations (or CDMOs) has seen tremendous growth and change as a result of the COVID-19 pandemic. An unprecedented demand for CDMO services resulted from the pressing need for vaccines, treatments, and diagnostic tools, which sped up production schedules and increased manufacturing capacity. Furthermore, the rapid development and widespread manufacturing of COVID-19 vaccines and treatments were made possible in large part by CDMOs, underscoring the significance of these organizations in the biopharmaceutical supply chain.

The Biologics segment is expected to be the largest during the forecast period

In the biologics contract development and manufacturing organization (CDMO) market, the biologics segment has the largest market share. Biologics comprise a broad spectrum of intricate medicinal items, such as recombinant proteins, cell and gene therapies, vaccines, and monoclonal antibodies. The market for biologics has expanded due to the rising incidence of chronic illnesses and the rising need for individualized and targeted treatments. Moreover, pharmaceutical companies have made significant investments in the development and commercialization of biologics due to their significant therapeutic advantages over traditional small-molecule drugs.

The Contract Manufacturing Organization (CMO) segment is expected to have the highest CAGR during the forecast period

In the biologics contract development and manufacturing organization (CDMO) market, the contract manufacturing organization (CMO) segment usually shows the highest CAGR. CMOs are experts in offering biopharmaceutical products end-to-end manufacturing services, encompassing process development, scaling up, and commercial production. Additionally, pharmaceutical companies outsource manufacturing to CMOs due to the growing demand for biologics, complex manufacturing processes, and the requirement for specialized expertise.

Region with largest share:

In the biologics contract development and manufacturing organization (CDMO) market, North America typically holds the largest share. Numerous elements contribute to the region's dominance, such as a thriving biopharmaceutical sector, state-of0-the-art healthcare facilities, a solid regulatory environment, and a highly qualified labour force. Furthermore, a thriving ecosystem for the development and production of biologics is fostered by the large number of biotech and pharmaceutical companies, as well as eminent academic and research institutions located in North America.

Region with highest CAGR:

In the market for biologics contract development and manufacturing organizations (CDOs), the Asia-Pacific region usually shows the highest CAGR. Increasing outsourcing among biopharmaceutical companies, growing investments in healthcare infrastructure and growing biopharmaceutical manufacturing capabilities in nations like China, India, and South Korea are some of the factors driving this growth. Moreover, the region's appeal to CDMOs is further enhanced by advantageous government policies, regulatory reforms, and initiatives to support biotech innovation.

Key players in the market

Some of the key players in Biologics Contract Development and Manufacturing Organization (CDMO) market include Samsung Biologics, Boehringer Ingelheim Group, Sandoz Biopharmaceuticals (Novartis AG), Parexel International Corporation, Fujifilm Diosynth Biotechnologies USA Inc., AbbVie Contract Manufacturing, Lonza Group, Binex Co. Limited, Rentschler Biotechnologies, Toyobo Co. Limited, AGC Biologics, PRA Health Sciences, Catalent Inc, Wuxi Biologics and JRS Pharma.

Key Developments:

In May 2024, AbbVie and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.

In April 2024, FUJIFILM Diosynth Biotechnologies, a global leading contract development and manufacturing organization (CDMO), announced that it will expand its large-scale cell culture manufacturing facility currently under construction with a $1.2 billion investment from FUJIFILM Corporation.

In February 2024, Samsung Biologics, a global contract development and manufacturing organization (CDMO), has signed a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

Products Covered:
• Biosimilars
• Biologics
• Other Products

Services Covered:
• Contract Manufacturing Organization (CMO)
• Contract Research Organization (CRO)

Types Covered:
• Mammalian
• Non-Mammalian (Microbial)
• Viral Vector
• Other Types

End Users Covered:
• Biotechnology Companies
• Biopharmaceutical Companies
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements